Evidence map›Paper›PMID 26203860›Full record

ReviewCell death & disease2015

Genome-editing tools for stem cell biology.

E A Vasileva, O U Shuvalov, A V Garabadgiu, G Melino, N A Barlev

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

E A VasilevaInstitute of Cytology, RAS, Saint-Petersburg, Russia.
O U ShuvalovInstitute of Cytology, RAS, Saint-Petersburg, Russia.
A V GarabadgiuTechnological University, Saint-Petersburg, Russia.
G Melino1] Technological University, Saint-Petersburg, Russia [2] MRC Toxicology Unit, Leicester, UK.
N A Barlev1] Institute of Cytology, RAS, Saint-Petersburg, Russia [2] Technological University, Saint-Petersburg, Russia.
St. Petersburg State Technological Institute · RUInstitute of Cytology · RU

Funding

Medical Research Council MC_U132670600
6 · The paper itself

Abstract

Human pluripotent stem cells provide a versatile platform for regenerative studies, drug testing and disease modeling. That the expression of only four transcription factors, Oct4, Klf4, Sox2 and c-Myc (OKSM), is sufficient for generation of induced pluripotent stem cells (iPSCs) from differentiated somatic cells has revolutionized the field and also highlighted the importance of OKSM as targets for genome editing. A number of novel genome-editing systems have been developed recently. In this review, we focus on successful applications of several such systems for generation of iPSCs. In particular, we discuss genome-editing systems based on zinc-finger fusion proteins (ZFs), transcription activator-like effectors (TALEs) and an RNA-guided DNA-specific nuclease, Cas9, derived from the bacterial defense system against viruses that utilizes clustered regularly interspaced short palindromic repeats (CRISPR).

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsGenome, HumanBacterial ProteinsBiomarkersCell DifferentiationCRISPR-Associated Protein 9EndonucleasesGene ExpressionHomeodomain ProteinsHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsOctamer Transcription Factor-3Pluripotent Stem CellsProto-Oncogene Proteins c-mycRepressor ProteinsBacterial ProteinsBiomarkersCas9 protein, Francisella novicidaCRISPR-Associated Protein 9EndonucleasesHomeodomain ProteinsKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMYC protein, humanOctamer Transcription Factor-3POU5F1 protein, humanProto-Oncogene Proteins c-mycRepressor ProteinsSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID26203860
PMCPMC4650720
OpenAlexW1961543354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.